



NEWS
FOR IMMEDIATE RELEASE
24 September 2008

Contact:

Audrey Honig Geragosian
Communications and Media Relations Manager
Connecticut State Medical Society
860.906.8037

Gualberto Rúaño, MD, PhD
President and CEO
Genomas, Inc.
860.545.4574

CONNECTICUT STATE MEDICAL SOCIETY AND GENOMAS CO-SPONSOR FORUM
on *DNA-GUIDED MEDICINE AND THE PATH TO PERSONALIZED HEALTH CARE*
FDA Expert on Pharmacogenomics Offers a Prescription for Progress

Waterbury, CT – The Connecticut State Medical Society is joining with Genomas[®], a biomedical company advancing DNA-guided medicine and personalized healthcare, to co-sponsor a symposium – *DNA-Guided Medicine and the Path to Personalized Health Care* – being held today at the Society’s annual meeting. Hartford Hospital is providing continuing medical education credits for physicians attending the meeting.

“The Society is delighted to be a co-sponsor of this important seminar at our Annual Meeting. We look forward to learning more about the efforts at Genomas and the FDA to move personalized medicine into clinical practice,” said Michael M. Deren, M.D., Chairman of the Board of the Connecticut State Medical Society. “We are grateful to Hartford Hospital for providing educational credit to our membership in this vital new area of medicine.”

Lawrence J. Lesko, Ph.D., Director of the Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, will discuss *FDA Initiatives in Personalized Medicine: Advancing Individualized Drug Therapy*. As an example of the agency’s efforts to move pharmacogenetic information into everyday practice, prescribing information was recently updated for the widely prescribed blood thinner warfarin (Coumadin[®]). These changes advise doctors that some patients can respond very differently to the drug and require lower doses if they happen to carry certain genetic variations. In psychiatry, Cytochrome P450 genes determine the metabolism of many drugs, among them atomoxetine (Strattera[®]) and paroxetine (Paxil[®]), commonly used, respectively, for attention deficit hyperactivity disorder and depression. Labels for these medicines warn about consequences of drug metabolism interactions to avoid side effects.

“The U.S. Department of Health and Human Services and the FDA have prioritized personalized medicine as one of its mission goals for public health. I am glad to participate in this event with the Connecticut Medical Society, Hartford Hospital and Genomas to bring these initiatives to

physicians who are in an important position to implement them in their clinical practice,” said Dr. Lesko. “Connecticut is poised to become one of the national leaders in adoption of personalized medicine, and I am thrilled to join ranks with these local efforts as exemplary to improving the healthcare system as a whole.”

Gualberto Rúaño, M.D., Ph.D., President and CEO of Genomas, and Director of Genetics Research, Hartford Hospital, will speak about *Progress Toward DNA-Guided Medicine in Clinical Practice: Case Studies in Cardiology and Psychiatry*. Examples in these two therapeutic areas include statins for managing elevated low-density lipoprotein cholesterol (LDLc), and atypical antipsychotics for the treatment of schizophrenia and bipolar disorders. Genomas is conducting clinical studies to uncover class-wide and drug-specific genetic associations between statins and neuromyopathy, which can be debilitating and reduce patient adherence to drug therapy. Statin-induced neuromyopathy (SINM) may present as muscle aches (myalgia), cramps, weakness and muscle injury (myositis). In another clinical study with a potentially large impact on public health, the Company is assessing patients treated with antipsychotics to identify genetic variations more commonly found in individuals who develop metabolic syndrome, a condition that includes changes in blood lipids, blood glucose, blood pressure and body weight. An estimated 15 to 18 percent of these individuals are at risk of drug-induced diabetes.

“We are privileged to partner with the Connecticut Medical Society to convene the physicians in our state for this forum. The presence of the FDA is an indication of the national impact of the programs in DNA-Guided Medicine that Genomas has spearheaded in Connecticut with Hartford Hospital and the Hospital of Central Connecticut,” said Dr. Rúaño. “Together, we are bringing personalized healthcare to our patients today, and setting the pathway to utilization of DNA-Guided Medicine as the standard of care in cardiovascular and psychiatric clinical practice.”

Neil Yeston, M.D., Vice President of Academic Affairs at Hartford Hospital commented: “The collaborative translational research between Genomas and Hartford Hospital has provided some crucial information that has already helped a number of patients avoid potentially life-threatening side effects. This important research could eventually help millions of patients. We should all take great pride that this contribution was made possible as a result of this important partnership. We congratulate the Connecticut State Medical Society and Genomas in organizing and hosting this important symposium in personalized medicine.”

ABOUT THE CONNECTICUT STATE MEDICAL SOCIETY

Founded in 1792, the Connecticut State Medical Society (CSMS) is a federation of eight component county medical associations, and the state's largest professional organization for physicians, with a total membership exceeding 7,000. CSMS itself is a constituent state entity of the American Medical Association. For more information, please visit www.csms.org.

ABOUT GENOMAS

Genomas Inc. is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company develops revolutionary PhyzioType™ Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs in cardiovascular and psychiatric medicine. PhyzioType Systems are designed to provide physicians with the unprecedented capability to select for each patient the safest drug treatment to enhance compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. For more information, please visit www.genomas.net

###